[Lu-177]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

- Hofman, Michael S., Emmett, Louise, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Sandhu, Shahneen, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A., Williams, Scott G., Iravani, Amir, Martin, Andrew J., Davis, Ian D., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

- Hofman, Michael S., Lawrentschuk, Nathan, Wong, Lih-Ming, Taubman, Kim, Ting Lee, Sze, Hsiao, Edward, Roach, Paul, Nottage, Michelle, Kirkwood, Ian, Hayne, Dickon, Link, Emma, Marusic, Petra, Francis, Roslyn J., Matera, A, Herschtal, A, Iravani, A, Hicks, RJ, Williams, S, Murphy, DG, Tang, Colin, Vela, Ian, Thomas, Paul, Rutherford, Natalie, Martin, Jarad M., Frydenberg, Mark, Shakher, Ramdave